Product Information
TOPIRAMATE ER 25 MG SPRINKL CAP is a generic product labeled by Vitruvias Therapeutics Inc., priced at $2.2543 per EA under NDC 69680017730. Its NADAC has been published 65 times since Jul 9, 2025.
FDA first approved this application on Nov 5, 2024. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680017730
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA215638FDA Approved
11/5/2024
TE Code
AB2
On Market Since
4/7/2025
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 25 MG SPRINKL CAP has been published 65 times since Jul 9, 2025, and over the history we have for it it has declined 39.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2543 per EA |
|---|---|
| All-time high | $3.8264 (Sep 10, 2025) |
| All-time low | $2.2543 (Sep 23, 2026) |
| 52-week high | $3.7915 |
| 52-week low | $2.2543 |
| Median price | $3.5762 |
| Average price | $3.2883 |
| Largest weekly change | -9.3% (May 20, 2026) |
| Weeks tracked | 65 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 89% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 25 MG SPRINKL CAP?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 25 MG SPRINKL CAP, manufactured by Vitruvias Therapeutics Inc., is $2.2543 per EA (NDC 69680017730), effective Sep 30, 2026.
How has the price of TOPIRAMATE ER 25 MG SPRINKL CAP changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 25 MG SPRINKL CAP has declined 39.3%. It has been tracked across 65 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 25 MG SPRINKL CAP?
Since Jul 9, 2025, the NADAC for TOPIRAMATE ER 25 MG SPRINKL CAP has ranged from a low of $2.2543 (Sep 23, 2026) to a high of $3.8264 (Sep 10, 2025), with a median of $3.5762 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 25 MG SPRINKL CAP?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE 25 MG SPRINKLE CAP, is $0.2459 per EA — about 89% below TOPIRAMATE ER 25 MG SPRINKL CAP.
Who manufactures TOPIRAMATE ER 25 MG SPRINKL CAP?
TOPIRAMATE ER 25 MG SPRINKL CAP (NDC 69680017730) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.